Sponsor Pipeline

Candel Therapeutics, Inc. Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-08-16
5
Active Trials
2
Recruiting
2
Phase 3
3
Disease Areas
1
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-08-09 NCT02446093
Neoadjuvant CAN-2409 in Combination With Chemoradiation or SBRT for Borderline Resectable…		 overall status: Active, Not Recruiting → Unknown
Active Trials by Phase
Phase 3
2
Phase 2
3
Active Trials
NCT IDTitleConditionStatus
Phase 3
NCT07660094 Aglatimagene Besadenovec + Prodrug and Pembrolizumab vs Docetaxel for Stage IV… Non-squamous, Non-Small Cell Lung Cancer Recruiting
NCT01436968 Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized… Prostate Cancer Active, Not Recruiting
Phase 2
NCT07332000 A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene… Prostate Cancer Patients Treated by Radiotherapy Recruiting
NCT02768363 Randomized Controlled Trial of CAN-2409 Immunotherapy During Active Surveillance for… Prostate Cancer Active, Not Recruiting
NCT04495153 CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV… Non Small Cell Lung Cancer Active, Not Recruiting
Disease Areas
Prostate Cancer (3) Non-Small Cell Lung Cancer (NSCLC) (2) Lung Cancer (2)
Get alerts when Candel Therapeutics, Inc.'s trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free